Kura Oncology (KURA)
Kura Oncology on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
14.3M
Short interest
settlement 2026-10-15
8.6
Days to cover
+0.8 days vs prior
73.3%
Short share of volume
2026-11-02
429
Fails to deliver
settlement 2026-10-08
Tue 3 Nov
Next earnings
estimated date
$643K
Insider flow, 90 days
2 buys, 12 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in KURA is 14,319,826 shares, down 500,766 shares over the last month. Over the last 48 readings it ranged from 7,310,547 shares (29 November 2024) to 15,643,393 shares (15 May 2026). At the reported average volume of 1.7M shares a day that is 8.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/kura" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 14,319,826 | -0.7% | 1,668,947 | 8.58 |
| 2026-09-30 | 14,419,736 | -2.7% | 1,864,560 | 7.73 |
| 2026-09-15 | 14,820,592 | +10.5% | 1,686,050 | 8.79 |
| 2026-08-31 | 13,417,317 | +2.2% | 2,802,191 | 4.79 |
| 2026-08-14 | 13,124,869 | -0.3% | 1,486,356 | 8.83 |
| 2026-07-31 | 13,160,945 | -4.2% | 1,114,002 | 11.81 |
| 2026-07-15 | 13,732,567 | -9.0% | 1,780,779 | 7.71 |
| 2026-06-30 | 15,092,162 | +3.4% | 1,760,214 | 8.57 |
| 2026-06-15 | 14,602,804 | +7.4% | 1,990,843 | 7.33 |
| 2026-05-29 | 13,592,010 | -13.1% | 2,554,793 | 5.32 |
| 2026-05-15 | 15,643,393 | +1.4% | 1,370,276 | 11.42 |
| 2026-04-30 | 15,431,271 | +2.8% | 1,314,981 | 11.73 |
| 2026-04-15 | 15,008,317 | +5.7% | 1,399,679 | 10.72 |
| 2026-03-31 | 14,202,891 | -1.2% | 1,293,831 | 10.98 |
| 2026-03-13 | 14,375,228 | -1.4% | 1,784,485 | 8.06 |
| 2026-02-27 | 14,584,763 | +3.8% | 1,385,598 | 10.53 |
| 2026-02-13 | 14,045,051 | +3.1% | 1,362,871 | 10.31 |
| 2026-01-30 | 13,626,588 | +10.7% | 1,367,803 | 9.96 |
| 2026-01-15 | 12,311,880 | +8.8% | 1,424,946 | 8.64 |
| 2025-12-31 | 11,310,507 | +37.5% | 1,786,858 | 6.33 |
| 2025-12-15 | 8,223,035 | +2.9% | 1,506,450 | 5.46 |
| 2025-11-28 | 7,990,490 | -8.6% | 1,618,510 | 4.94 |
| 2025-11-14 | 8,744,761 | +0.8% | 2,609,233 | 3.35 |
| 2025-10-31 | 8,675,680 | -18.2% | 1,999,973 | 4.34 |
| 2025-10-15 | 10,610,088 | +1.9% | 1,776,646 | 5.97 |
| 2025-09-30 | 10,412,057 | -4.0% | 1,662,154 | 6.26 |
| 2025-09-15 | 10,849,204 | +29.0% | 1,765,339 | 6.15 |
| 2025-08-29 | 8,407,325 | +5.1% | 1,962,189 | 4.28 |
| 2025-08-15 | 7,996,034 | +1.1% | 1,871,836 | 4.27 |
| 2025-07-31 | 7,906,891 | -5.9% | 1,255,969 | 6.30 |
| 2025-07-15 | 8,406,094 | +7.0% | 1,320,681 | 6.36 |
| 2025-06-30 | 7,859,540 | -0.5% | 1,442,584 | 5.45 |
| 2025-06-13 | 7,896,747 | -5.5% | 1,258,725 | 6.27 |
| 2025-05-30 | 8,357,660 | +5.1% | 1,212,337 | 6.89 |
| 2025-05-15 | 7,952,707 | -4.0% | 1,189,651 | 6.68 |
| 2025-04-30 | 8,283,602 | -4.5% | 991,399 | 8.36 |
| 2025-04-15 | 8,677,940 | -1.4% | 1,920,854 | 4.52 |
| 2025-03-31 | 8,802,791 | -2.4% | 987,710 | 8.91 |
| 2025-03-14 | 9,022,023 | -2.1% | 1,349,790 | 6.68 |
| 2025-02-28 | 9,211,838 | -0.4% | 1,030,884 | 8.94 |
| 2025-02-14 | 9,249,137 | +14.5% | 2,353,858 | 3.93 |
| 2025-01-31 | 8,075,542 | -0.8% | 1,461,077 | 5.53 |
| 2025-01-15 | 8,139,947 | -22.0% | 1,466,791 | 5.55 |
| 2024-12-31 | 10,435,685 | +17.4% | 1,981,196 | 5.27 |
| 2024-12-13 | 8,888,988 | +21.6% | 1,559,255 | 5.70 |
| 2024-11-29 | 7,310,547 | -33.8% | 4,385,877 | 1.67 |
| 2024-11-15 | 11,034,861 | +2.2% | 893,474 | 12.35 |
| 2024-10-31 | 10,801,665 | +16.2% | 611,676 | 17.66 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of KURA volume is 73.3%, up 18.1 points over the last five sessions. Over the last 30 readings it ranged from 38.3% (22 September 2026) to 79.3% (23 October 2026). The latest reading is 12.7 points above the 30-session average of 60.6%, on 362K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 265K | 362K | 73.3% | 563 |
| 2026-10-30 | 554K | 747K | 74.1% | 710 |
| 2026-10-29 | 297K | 572K | 51.9% | 1,546 |
| 2026-10-28 | 513K | 890K | 57.7% | 1,204 |
| 2026-10-27 | 349K | 704K | 49.6% | 1,466 |
| 2026-10-26 | 145K | 263K | 55.3% | 20 |
| 2026-10-23 | 644K | 811K | 79.3% | 0 |
| 2026-10-22 | 208K | 324K | 64.1% | 0 |
| 2026-10-21 | 204K | 334K | 60.9% | 0 |
| 2026-10-20 | 422K | 631K | 66.9% | 12 |
| 2026-10-19 | 605K | 955K | 63.4% | 0 |
| 2026-10-16 | 511K | 766K | 66.6% | 0 |
| 2026-10-15 | 416K | 649K | 64.1% | 15 |
| 2026-10-14 | 387K | 618K | 62.6% | 1,807 |
| 2026-10-13 | 724K | 1.2M | 62.1% | 0 |
| 2026-10-12 | 390K | 591K | 65.9% | 500 |
| 2026-10-09 | 291K | 526K | 55.2% | 0 |
| 2026-10-08 | 253K | 510K | 49.7% | 3,377 |
| 2026-10-07 | 297K | 466K | 63.7% | 6,182 |
| 2026-10-06 | 296K | 499K | 59.4% | 2,979 |
| 2026-10-05 | 202K | 412K | 49.1% | 0 |
| 2026-10-02 | 455K | 790K | 57.6% | 0 |
| 2026-10-01 | 650K | 1.0M | 64.0% | 0 |
| 2026-09-30 | 308K | 536K | 57.4% | 2,176 |
| 2026-09-29 | 430K | 697K | 61.7% | 0 |
| 2026-09-28 | 375K | 703K | 53.3% | 1,045 |
| 2026-09-25 | 288K | 460K | 62.7% | 2,105 |
| 2026-09-24 | 489K | 660K | 74.1% | 5,969 |
| 2026-09-23 | 789K | 1.5M | 53.6% | 50 |
| 2026-09-22 | 244K | 637K | 38.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 October 2026, the fails-to-deliver balance in KURA is 429 shares, down 2,534 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (9 April 2026) to 249,845 shares (1 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-08 | 429 | $10.67 | $5K |
| 2026-09-17 | 2,963 | $11.20 | $33K |
| 2026-09-04 | 465 | $13.15 | $6K |
| 2026-08-31 | 97 | $12.66 | $1K |
| 2026-08-24 | 100 | $11.89 | $1K |
| 2026-08-11 | 967 | $9.85 | $10K |
| 2026-07-22 | 581 | $10.89 | $6K |
| 2026-07-10 | 5,372 | $12.08 | $65K |
| 2026-07-09 | 5,372 | $12.12 | $65K |
| 2026-07-08 | 8,208 | $11.99 | $98K |
| 2026-07-02 | 4,543 | $10.78 | $49K |
| 2026-06-30 | 2,603 | $10.97 | $29K |
| 2026-06-26 | 3,526 | $10.36 | $37K |
| 2026-06-24 | 22 | $10.38 | $228 |
| 2026-06-18 | 50 | $9.57 | $479 |
| 2026-06-08 | 22,161 | $8.74 | $194K |
| 2026-06-01 | 249,845 | $10.20 | $2.5M |
| 2026-05-28 | 1,343 | $10.24 | $14K |
| 2026-05-26 | 693 | $11.25 | $8K |
| 2026-05-19 | 802 | $9.20 | $7K |
| 2026-04-22 | 431 | $9.47 | $4K |
| 2026-04-20 | 15,431 | $9.68 | $149K |
| 2026-04-09 | 3 | $8.79 | $26 |
| 2026-03-19 | 11,102 | $8.39 | $93K |
| 2026-03-17 | 116,807 | $8.73 | $1.0M |
| 2026-03-16 | 116,807 | $8.65 | $1.0M |
| 2026-03-02 | 1,935 | $8.73 | $17K |
| 2026-02-24 | 17 | $8.35 | $142 |
| 2026-02-18 | 4,934 | $8.48 | $42K |
| 2026-02-03 | 549 | $8.27 | $5K |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days KURA insiders reported 2 open-market buys ($2.4M) against 12 sells ($1.7M), so the dollar flow leans toward buying. Latest filing: Powl Brian T. (Chief Commercial Officer) on 2026-09-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Powl Brian T. | Chief Commercial Officer | Sell | 15K | $10.75 | $166K | 137K |
| 2026-09-29 | Leoni Mollie | Chief Medical Officer | Sell | 29K | $10.75 | $310K | 141K |
| 2026-09-29 | FORD KATHLEEN | Chief Operating Officer | Sell | 4K | $10.75 | $39K | 143K |
| 2026-09-28 | Powl Brian T. | Chief Commercial Officer | Sell | 8K | $10.56 | $84K | 152K |
| 2026-09-28 | Powl Brian T. | Chief Commercial Officer | Sell | 9K | $10.50 | $95K | 160K |
| 2026-09-28 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 5K | $10.50 | $48K | 142K |
| 2026-09-28 | Leoni Mollie | Chief Medical Officer | Sell | 12K | $10.50 | $131K | 170K |
| 2026-09-28 | FORD KATHLEEN | Chief Operating Officer | Sell | 7K | $10.50 | $72K | 147K |
| 2026-09-28 | Bair Teresa Brophy | Chief Legal Officer | Sell | 8K | $10.50 | $89K | 187K |
| 2026-09-24 | Burrows Francis | Chief Scientific Officer | Sell | 21K | $10.83 | $225K | 42K |
| 2026-09-24 | Burrows Francis | Chief Scientific Officer | Exercise or conversion | 30K | $6.15 | $185K | 63K |
| 2026-08-24 | WILSON TROY EDWARD | President and CEO | Buy | 100K | $12.39 | $1.2M | 479K |
| 2026-08-21 | Powl Brian T. | Chief Commercial Officer | Sell | 4K | $11.89 | $52K | 169K |
| 2026-08-19 | Bair Teresa Brophy | Chief Legal Officer | Sell | 31K | $12.63 | $398K | 195K |
| 2026-08-17 | WILSON TROY EDWARD | President and CEO | Buy | 100K | $11.12 | $1.1M | 379K |
| 2026-06-18 | Leoni Mollie | Chief Medical Officer | Sell | 85K | $9.82 | $834K | 182K |
| 2026-05-21 | Powl Brian T. | Chief Commercial Officer | Sell | 10K | $11.00 | $110K | 174K |
| 2026-05-19 | Powl Brian T. | Chief Commercial Officer | Sell | 339 | $9.21 | $3K | 184K |
| 2026-05-19 | FORD KATHLEEN | Chief Operating Officer | Sell | 2K | $9.08 | $20K | 154K |
| 2026-05-18 | Bair Teresa Brophy | Chief Legal Officer | Sell | 2K | $9.38 | $21K | 227K |
| 2026-03-23 | WILSON TROY EDWARD | President and CEO | Exercise or conversion | 6K | $6.15 | $38K | 435K |
| 2026-03-18 | Malley Thomas | Director | Exercise or conversion | 10K | $3.12 | $31K | 10K |
| 2026-01-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 2K | $8.46 | $19K | 146K |
| 2026-01-27 | Powl Brian T. | Chief Commercial Officer | Sell | 2K | $8.46 | $13K | 183K |
| 2026-01-27 | Powl Brian T. | Chief Commercial Officer | Sell | 5K | $8.46 | $41K | 185K |
| 2026-01-27 | Leoni Mollie | Chief Medical Officer | Sell | 1K | $8.46 | $11K | 267K |
| 2026-01-27 | Leoni Mollie | Chief Medical Officer | Sell | 951 | $8.46 | $8K | 269K |
| 2026-01-27 | Leoni Mollie | Chief Medical Officer | Sell | 2K | $8.46 | $19K | 270K |
| 2026-01-27 | Leoni Mollie | Chief Medical Officer | Sell | 4K | $8.46 | $31K | 272K |
| 2026-01-27 | FORD KATHLEEN | Chief Operating Officer | Sell | 2K | $8.46 | $15K | 154K |
| 2026-01-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 881 | $8.46 | $7K | 145K |
| 2026-01-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 695 | $8.46 | $6K | 148K |
| 2026-01-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 1K | $8.46 | $9K | 149K |
| 2026-01-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 2K | $8.46 | $19K | 150K |
| 2026-01-27 | Burrows Francis | Chief Scientific Officer | Sell | 1K | $8.46 | $11K | 32K |
| 2026-01-27 | Bair Teresa Brophy | Chief Legal Officer | Sell | 5K | $8.46 | $40K | 227K |
| 2026-01-27 | Bair Teresa Brophy | Chief Legal Officer | Sell | 2K | $8.46 | $20K | 232K |
| 2026-01-27 | Bair Teresa Brophy | Chief Legal Officer | Sell | 4K | $8.46 | $35K | 234K |
| 2026-01-02 | Leoni Mollie | Chief Medical Officer | Grant | 50K | $0.00 | $0 | 275K |
| 2026-01-02 | Powl Brian T. | Chief Commercial Officer | Grant | 50K | $0.00 | $0 | 190K |
| 2026-01-02 | FORD KATHLEEN | Chief Operating Officer | Grant | 50K | $0.00 | $0 | 155K |
| 2026-01-02 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Grant | 21K | $0.00 | $0 | 152K |
| 2026-01-02 | Bair Teresa Brophy | Chief Legal Officer | Grant | 50K | $0.00 | $0 | 238K |
| 2025-12-18 | Burrows Francis | Chief Scientific Officer | Sell | 24K | $9.78 | $232K | 34K |
| 2025-12-18 | Burrows Francis | Chief Scientific Officer | Exercise or conversion | 35K | $4.80 | $168K | 57K |
| 2025-12-09 | Hasnain Faheem | Director | Sell | 10K | $10.98 | $110K | 24K |
| 2025-12-09 | Hasnain Faheem | Director | Exercise or conversion | 10K | $3.12 | $31K | 34K |
| 2025-11-14 | Powl Brian T. | Chief Commercial Officer | Sell | 9K | $11.18 | $99K | 140K |
| 2025-11-14 | Leoni Mollie | Chief Medical Officer | Sell | 15K | $11.18 | $173K | 225K |
| 2025-11-14 | FORD KATHLEEN | Chief Operating Officer | Sell | 7K | $11.18 | $77K | 105K |
| 2025-11-14 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 5K | $11.18 | $51K | 130K |
| 2025-11-14 | Bair Teresa Brophy | Chief Legal Officer | Sell | 9K | $11.18 | $98K | 188K |
| 2025-11-13 | WILSON TROY EDWARD | President and CEO | Grant | 183K | $0.00 | $0 | 429K |
| 2025-11-13 | Powl Brian T. | Chief Commercial Officer | Grant | 49K | $0.00 | $0 | 149K |
| 2025-11-13 | Leoni Mollie | Chief Medical Officer | Grant | 83K | $0.00 | $0 | 241K |
| 2025-11-13 | FORD KATHLEEN | Chief Operating Officer | Grant | 49K | $0.00 | $0 | 112K |
| 2025-11-13 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Grant | 25K | $0.00 | $0 | 135K |
| 2025-11-13 | Bair Teresa Brophy | Chief Legal Officer | Grant | 49K | $0.00 | $0 | 197K |
| 2025-09-29 | Powl Brian T. | Chief Commercial Officer | Sell | 9K | $8.94 | $80K | 100K |
| 2025-09-29 | Leoni Mollie | Chief Medical Officer | Sell | 12K | $8.94 | $110K | 158K |
| 2025-09-29 | WILSON TROY EDWARD | President and CEO | Sell | 37K | $8.94 | $327K | 247K |
| 2025-09-29 | FORD KATHLEEN | Chief Operating Officer | Sell | 7K | $8.94 | $62K | 63K |
| 2025-09-29 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 5K | $8.94 | $41K | 110K |
| 2025-09-29 | Bair Teresa Brophy | Chief Legal Officer | Sell | 9K | $8.94 | $79K | 148K |
| 2025-09-27 | Powl Brian T. | Chief Commercial Officer | Grant | 49K | $0.00 | $0 | 109K |
| 2025-09-27 | Leoni Mollie | Chief Medical Officer | Grant | 83K | $0.00 | $0 | 171K |
| 2025-09-27 | WILSON TROY EDWARD | President and CEO | Grant | 183K | $0.00 | $0 | 283K |
| 2025-09-27 | FORD KATHLEEN | Chief Operating Officer | Grant | 49K | $0.00 | $0 | 70K |
| 2025-09-27 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Grant | 25K | $0.00 | $0 | 114K |
| 2025-09-27 | Bair Teresa Brophy | Chief Legal Officer | Grant | 49K | $0.00 | $0 | 157K |
| 2025-09-08 | WILSON TROY EDWARD | President & CEO | Buy | 50K | $8.20 | $410K | 101K |
| 2025-08-13 | WILSON TROY EDWARD | President and CEO | Buy | 13K | $6.64 | $90K | 51K |
| 2025-08-12 | WILSON TROY EDWARD | President and CEO | Buy | 37K | $5.85 | $214K | 37K |
| 2025-05-19 | FORD KATHLEEN | Chief Operating Officer | Sell | 2K | $6.28 | $10K | 21K |
| 2025-05-19 | Bair Teresa Brophy | Chief Legal Officer | Sell | 2K | $5.96 | $9K | 108K |
| 2025-03-21 | Hasnain Faheem | Director | Sell | 23K | $8.00 | $181K | 24K |
| 2025-03-21 | Hasnain Faheem | Director | Exercise or conversion | 23K | $6.32 | $143K | 47K |
| 2025-01-28 | Powl Brian T. | Chief Commercial Officer | Sell | 2K | $7.87 | $12K | 60K |
| 2025-01-28 | Burrows Francis | Chief Scientific Officer | Sell | 846 | $7.87 | $7K | 22K |
| 2025-01-28 | Burrows Francis | Chief Scientific Officer | Sell | 1K | $7.87 | $10K | 21K |
| 2025-01-28 | FORD KATHLEEN | Chief Operating Officer | Sell | 2K | $7.87 | $14K | 21K |
| 2025-01-28 | Bair Teresa Brophy | Chief Legal Officer | Sell | 2K | $7.87 | $19K | 113K |
| 2025-01-28 | Bair Teresa Brophy | Chief Legal Officer | Sell | 5K | $7.87 | $38K | 108K |
| 2025-01-28 | Leoni Mollie | Chief Medical Officer | Sell | 1K | $7.87 | $11K | 90K |
| 2025-01-28 | Leoni Mollie | Chief Medical Officer | Sell | 816 | $7.87 | $6K | 89K |
| 2025-01-28 | Leoni Mollie | Chief Medical Officer | Sell | 541 | $7.87 | $4K | 88K |
| 2025-01-28 | Leoni Mollie | Chief Medical Officer | Sell | 2K | $7.87 | $18K | 91K |
| 2025-01-28 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 1K | $7.87 | $9K | 88K |
| 2025-01-28 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 887 | $7.87 | $7K | 90K |
| 2025-01-28 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 699 | $7.87 | $6K | 89K |
| 2025-01-28 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 2K | $7.87 | $18K | 91K |
| 2025-01-02 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Grant | 21K | $0.00 | $0 | 93K |
| 2025-01-02 | Powl Brian T. | Chief Commercial Officer | Grant | 46K | $0.00 | $0 | 61K |
| 2025-01-02 | Bair Teresa Brophy | Chief Legal Officer | Grant | 46K | $0.00 | $0 | 115K |
| 2025-01-02 | DOYLE THOMAS JAMES | SVP, Finance & Accounting | Grant | 21K | $0.00 | $0 | 72K |
| 2025-01-02 | Leoni Mollie | Chief Medical Officer | Grant | 46K | $0.00 | $0 | 93K |
| 2024-11-18 | FORD KATHLEEN | Chief Operating Officer | Sell | 526 | $16.03 | $8K | 23K |
| 2024-05-20 | Bair Teresa Brophy | Chief Legal Officer | Sell | 3K | $22.15 | $58K | 69K |
| 2024-01-30 | DALE STEPHEN | Chief Medical Officer | Sell | 5K | $21.55 | $104K | 39K |
| 2024-01-29 | DALE STEPHEN | Chief Medical Officer | Sell | 3K | $17.80 | $49K | 44K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON36 Form 144 notices on file for KURA worth $4.5M at the prices reported; 12 in the last 90 days worth $1.7M. Latest: KATHLEEN FORD filed on 2026-09-29 to sell 3,668 shares ($39K) from 2026-09-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-29 | KATHLEEN FORDOfficer | 4K | $39K | 0.004% | 2026-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-29 | MOLLIE LEONIOfficer | 29K | $306K | 0.032% | 2026-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-29 | BRIAN POWLOfficer | 15K | $164K | 0.017% | 2026-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | POWL BRIAN TOfficer | 9K | $97K | 0.010% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | DOYLE THOMAS JAMESOfficer | 5K | $50K | 0.005% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | FORD KATHLEENOfficer | 7K | $74K | 0.008% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | BAIR TERESA BROPHYOfficer | 8K | $91K | 0.009% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | LEONI MOLLIEOfficer | 12K | $134K | 0.014% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-28 | BRIAN POWLOfficer | 8K | $86K | 0.009% | 2026-09-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-24 | FRANCIS J BURROWSOfficer | 21K | $225K | 0.023% | 2026-09-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | BRIAN POWLOfficer | 4K | $51K | 0.005% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-19 | TERESA BAIROfficer | 31K | $388K | 0.035% | 2026-08-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-18 | MOLLIE VANESSA LEONIOfficer | 85K | $813K | 0.096% | 2026-06-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-21 | BRIAN POWLOfficer | 10K | $103K | 0.011% | 2026-05-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-19 | BRIAN POWLOfficer | 339 | $3K | 0.000% | 2026-05-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-19 | KATHLEEN FORDOfficer | 2K | $21K | 0.003% | 2026-05-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | TERESA BAIROfficer | 2K | $21K | 0.003% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | POWL BRIAN TOfficer | 6K | $54K | 0.007% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | LEONI MOLLIEOfficer | 8K | $69K | 0.009% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | FORD KATHLEENOfficer | 2K | $15K | 0.002% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | DOYLE THOMAS JAMESOfficer | 7K | $60K | 0.008% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | BURROWS FRANCISOfficer | 1K | $11K | 0.001% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | BAIR TERESA BROPHYOfficer | 11K | $95K | 0.013% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-18 | FRANCIS J BURROWSOfficer | 24K | $232K | 0.027% | 2025-12-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-09 | FAHEEM HASNAINDirector | 10K | $116K | 0.011% | 2025-12-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | POWL BRIAN TOfficer | 9K | $95K | 0.010% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | LEONI MOLLIEOfficer | 15K | $165K | 0.018% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | FORD KATHLEENOfficer | 7K | $74K | 0.008% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | DOYLE THOMAS JAMESOfficer | 5K | $48K | 0.005% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | BAIR TERESA BROPHYOfficer | 9K | $94K | 0.010% | 2025-11-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | POWL BRIAN TOfficer | 9K | $80K | 0.010% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | WILSON TROY EDWARDOfficer, Director | 37K | $331K | 0.042% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | LEONI MOLLIEOfficer | 12K | $111K | 0.014% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | FORD KATHLEENOfficer | 7K | $62K | 0.008% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | DOYLE THOMAS JAMESOfficer | 5K | $41K | 0.005% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-29 | BAIR TERESA BROPHYOfficer | 9K | $80K | 0.010% | 2025-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of KURA in their latest filing, all on Schedule 13G (passive). The largest reported stake is LAMPERT MARK N at 10.0% of the class (8,677,018 shares), filed 2025-11-14 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 8 | BlackRock, Inc.parent holding company | 7.9M | 8.9% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 6 | Montanova Capital, LLCinvestment adviser, other entity | 8.6M | 9.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 6 | Aaron Cowenparent holding company | 8.6M | 9.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 6 | Averill Master Fund, Ltd.corporation | 7.8M | 8.8% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 5 | Armistice Capital, LLCinvestment adviser, other entity | 3.7M | 4.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Steven Boydparent holding company, individual | 3.7M | 4.2% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 4.4M | 5.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-09 | 13G | STATE STREET CORPORATIONparent holding company | 4.9M | 5.7% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 8.7M | 10.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 8.7M | 10.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF INC/ILcorporation | 8.7M | 10.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 8.1M | 9.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF I GP LLCother entity | 4.4M | 5.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 4.4M | 5.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF II GP LLCother entity | 3.6M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 3.6M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Biotechnology Value Trading Fund OS LPpartnership | 447K | 0.5% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF Partners OS Ltd.corporation | 447K | 0.5% | 2025-09-30 |
13F holders
Tracked managers holding KURA at their latest 13F. JSON6 of the 30 tracked managers held KURA at their latest 13F, $72.7M in total at quarter-end prices. AQR Capital Management is the largest at $34.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 3.1M | $34.3M | 0.01% | +1.0M |
| Renaissance Technologies | 2026-06-30 | 1.7M | $18.3M | 0.03% | +81K |
| Millennium Management | 2026-06-30 | 711K | $7.8M | 0.00% | -854K |
| Fisher Asset Management | 2026-06-30 | 626K | $6.9M | 0.00% | -49K |
| Citadel Advisors | 2026-06-30 | 328K | $3.6M | 0.00% | -41K |
| Two Sigma Investments | 2026-06-30 | 168K | $1.8M | 0.00% | -190K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Kura Oncology reported revenue of $20.9M, up 36.5% from the same quarter a year earlier, and net loss of $68.3M (-0.77 diluted EPS). In FY 2025 it generated -$64.1M of operating cash flow. As of 2026-06-30, cash was $70.2M against $5.6M of debt.
- Cash
- $70.2M
- Debt
- $5.6M
- Equity
- $48.4M
- Total assets
- $587.8M
- Shares outstanding
- 88,960,619
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $20.9M | -$68.3M | -327.3% | -0.77 |
| Q1 FY 2026 | 2026-03-31 | $18.3M | -$73.3M | -401.5% | -0.83 |
| Q4 FY 2025derived | 2025-12-31 | $17.3M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $20.8M | -$74.1M | -357.2% | -0.85 |
| Q2 FY 2025 | 2025-06-30 | $15.3M | -$66.1M | -432.5% | -0.75 |
| Q1 FY 2025 | 2025-03-31 | $14.1M | -$57.4M | -407.1% | -0.66 |
| Q4 FY 2024derived | 2024-12-31 | n/a | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$54.4M | n/a | -0.63 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $67.5M | -$278.7M | -$64.1M | $6.6M | n/a | n/a |
| FY 2024 | 2024-12-31 | $53.9M | -$174.0M | $134.3M | $472K | n/a | n/a |
| FY 2023 | 2023-12-31 | $0 | -$152.6M | -$124.8M | $168K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$135.8M | -$110.1M | $626K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$130.5M | -$104.6M | $1.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-07 from the cover page.
What this page is
Kura Oncology in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Kura Oncology (KURA), SEC CIK 1422143, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 1422143Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of KURA is sold short?
14,319,826 shares were held short at the 2026-10-15 settlement, 8.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KURA's daily short volume?
On 2026-11-02, 265,223 of the 361,661 KURA shares reported to FINRA were sold short, 73.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KURA have fails to deliver?
The SEC's latest file shows 429 KURA shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are KURA insiders buying or selling?
Over the last 90 days KURA insiders reported 2 open-market buys ($2.4M) against 12 sells ($1.7M), so the dollar flow leans toward buying. Latest filing: Powl Brian T. (Chief Commercial Officer) on 2026-09-29.
Have KURA insiders filed to sell?
36 Form 144 notices on file for KURA worth $4.5M at the prices reported; 12 in the last 90 days worth $1.7M. Latest: KATHLEEN FORD filed on 2026-09-29 to sell 3,668 shares ($39K) from 2026-09-29.
Who owns 5% or more of KURA?
12 holders report 5% or more of KURA in their latest filing, all on Schedule 13G (passive). The largest reported stake is LAMPERT MARK N at 10.0% of the class (8,677,018 shares), filed 2025-11-14 for an event on 2025-09-30.
What did KURA report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Kura Oncology reported revenue of $20.9M, up 36.5% from the same quarter a year earlier, and net loss of $68.3M (-0.77 diluted EPS). In FY 2025 it generated -$64.1M of operating cash flow. As of 2026-06-30, cash was $70.2M against $5.6M of debt.
Which tracked 13F managers own KURA?
6 of the 30 tracked 13F managers held KURA shares at their latest filing, $72.7M in all. The largest: Cliff Asness's AQR Capital Management (3.1M shares, $34.3M), Renaissance Technologies (1.7M shares, $18.3M), Izzy Englander's Millennium Management (711K shares, $7.8M), Ken Fisher's Fisher Asset Management (626K shares, $6.9M), Ken Griffin's Citadel Advisors (328K shares, $3.6M), Two Sigma Investments (168K shares, $1.8M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.